BioAge Labs (BIOA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, to be held virtually for stockholders of record as of April 16, 2026.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.
Voting matters and shareholder proposals
Election of three Class II directors for a three-year term: Patrick Enright, James I. Healy, and Rekha Hemrajani.
Ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be considered if properly brought before the meeting.
Board of directors and corporate governance
Board recommends a vote in favor of both director elections and auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BioAge Labs
- Lead program advanced to Phase 2, net loss widened, and cash reserves support operations through 2029.BIOA
Q2 2026 - Lead oral NLRP3 inhibitor advances in ASCVD and ophthalmology, with robust cash runway into 2026.BIOA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - BGE-102 achieved best-in-class CRP reduction and safety, advancing to pivotal Phase II trials.BIOA
R&D Day 2026 - BGE-102 advanced with strong Phase 1 data; $132.3M raised as net loss rose to $22.3M.BIOA
Q1 2026 - Annual meeting to elect directors and ratify auditor, with strong governance and risk oversight.BIOA
Proxy filing - Lead oral NLRP3 inhibitor shows strong Phase 1 results; major trials and $285M cash position.BIOA
Corporate presentation - BGE-102 achieved up to 86% CRP reduction and strong safety, advancing to Phase 2 trials.BIOA
Study result - BGE-102 shows best-in-class potential in inflammation, with pivotal trials and strong financial runway ahead.BIOA
25th Annual Needham Virtual Healthcare Conference - Oral NLRP3 inhibitor shows best-in-class CRP reduction; major clinical readouts expected this year.BIOA
Oppenheimer 36th Annual Healthcare Life Sciences Conference